Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Holding TNYA?
Track your performance easily
TNYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.61 - $7.01
Previous Close$2.57
Volume5.56M
Average Volume (3M)1.54M
Market Cap
$203.60M
Enterprise Value$138.67M
Total Cash (Recent Filing)$79.47M
Total Debt (Recent Filing)$14.54M
Price to Earnings (P/E)―
Beta3.27
Next Earnings
Mar 25, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding79,220,516
10 Day Avg. Volume7,659,647
30 Day Avg. Volume1,540,402
Standard Deviation0.30
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$19.67Price Target Upside790.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Tenaya Therapeutics News
PremiumStock Analysis & Ideas
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Tenaya Therapeutics Announces Board Restructuring and New Equity Plan
PremiumCompany Announcements
Tenaya Therapeutics Announces Key Interim Leadership AppointmentsBulls Say, Bears Say
Bulls Say
Financial StabilityTNYA ended the quarter with $79.5 million in cash, which is projected to be adequate into the second half of the following year, suggesting financial stability.
Gene Therapy DevelopmentThe company's 2nd gene therapy program, TN-401, is advancing with 6 clinical sites actively involved, indicating strong development momentum.
Research ProgressThe announcement of positive safety updates to cohort 1 of TN-201's MyPEAK-1 Ph1b/2 clinical trial boosts confidence in the company's research progress.
Bears Say
Financial PerformanceTNYA reported a net loss of $25.6 million for the third quarter of 2024.
Financial StabilityYears of cash left is approximately 0.8, indicating limited financial runway.
Leadership ChangesTenaya announced the departure of Leone Patterson, the chief financial and chief business officer, and Timothy Hoey, Ph.D., formerly Tenaya's chief scientific officer.
---
Ownership Overview
59.66% Insiders
11.43% Mutual Funds
1.94% Other Institutional Investors
19.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $1.61 and its highest was $7.01 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Currently, no data Available
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Mar 25, 2025 which is in 124 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.368 by $0.068.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -$0.31.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 79,220,510 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.368. Following the earnings report the stock price went up 12.108%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Among the largest hedge funds holding Tenaya Therapeutics’s share is RA Capital Management. It holds Tenaya Therapeutics’s shares valued at 24M.
---
Tenaya Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (790.05% Upside)
$19.67 (790.05% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.3%
Last 30 Days ▲ 139.2%
Last 30 Days ▲ 139.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.17%
12-Months-Change
Fundamentals
Return on Equity
-84.49%
Trailing 12-Months
Asset Growth
-27.31%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
---
TNYA Stock 12 Month Forecast
Average Price Target
$19.67
▲(790.05% Upside)
Technical Analysis
Allogene Therapeutics
―
Fate Therapeutics
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-5.34%
reiterated a buy rating 14 days ago
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -5.34% per trade.
---